Pharmacokinetics of Cyclosporin in Nephrotic Syndrome
The purpose of this study is to evaluate whether there are differences in the pharmacokinetics of cyclosporine in remission nephrotic syndrome compared to relapsed disease in children.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||PHARMACOKINETICS OF CYCLOSPORIN - A MICROEMULSION IN CHILDREN WITH IDIOPATHIC NEPHROTIC SYNDROME|
|Study Start Date:||February 2007|
|Study Completion Date:||February 2010|
|Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
Nephrotic patients in remission
Nephrotic patients in recidive
This is a prospective study on ten children using Cyclosporin-A (CSA) microemulsion to treat idiopathic nephrotic syndrome (INS), with normal renal function, who achieved complete remission with CSA. The objective is to compare the pharmacokinetic (PK) parameters of CSA in INS during remission and relapse of the disease. The PK profile of CSA was evaluated with the 12-hour area under the time-concentration curve (AUC0-12) using seven time-point samples. This procedure was done on each patient during remission and relapse with the same CSA dose in mg/kg/day. The AUC0-12 was calculated by trapezoidal rule. All PK parameters and the resumed 4-hour area under the time-concentration curve (AUC0-4) were correlated with AUC0-12. This study is very important because the cyclosporin is a nephrotoxic drug with narrow therapeutic window.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01616446
|Universidade de Sao Paulo|
|Sao Paulo, Brazil|